Mark Denison Archives
New study supports remdesivir as COVID-19 treatment
Jul. 9, 2020—This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.
Medical Scientist Training Program adapts to COVID-19 challenges
Apr. 16, 2020—The Medical Scientist Training Program has been intentional in approaching the challenges presented by COVID-19.
VUMC team aids development of potential antiviral drug for COVID-19
Apr. 6, 2020—Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.
Denison named director of Pediatric Infectious Diseases
Jul. 18, 2019—Mark Denison, MD, has been named director of the Division of Pediatric Infectious Diseases in the Vanderbilt Department of Pediatrics.
Team investigates antiviral that inhibits SARS, MERS
Jun. 29, 2017—A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators reports this week in Science Translational Medicine.
Medical societies honor four VUMC physicians
May. 12, 2016—Four physicians from Vanderbilt University Medical Center (VUMC) have been elected to membership in two of the nation’s oldest and most respected medical honor societies — the Association of American Physicians (AAP) and the American Society for Clinical Investigation (ASCI).
Pediatrics awarded physician-scientist training support
Feb. 18, 2016—The National Institutes of Health (NIH) has awarded Vanderbilt’s Department of Pediatrics a K12 training grant to support early career faculty to become physician-scientists, the first time the department has received such an award.
Contributors to coronavirus ‘fitness’
Feb. 24, 2015—Understanding the role that host membrane modification plays in coronavirus replication is essential for developing novel approaches to block the viruses that cause SARS and MERS.
‘Proofreader’ key to coronavirus growth
Sep. 12, 2013—A coronavirus protein is required for replication of the viral genome and may be a good treatment target for SARS and other diseases caused by coronaviruses.
UNC, Vanderbilt discover a new live vaccine approach for SARS and novel coronaviruses
Nov. 12, 2012—Collaborating researchers at the University of North Carolina and Vanderbilt University have found that accelerating the rate of mutations in the coronavirus responsible for deadly severe acute respiratory syndrome (SARS) cripples the virus’s ability to cause disease in animals.
New group of faculty endowed chairs celebrated
Sep. 28, 2011—Ten of Vanderbilt’s new endowed chairs were praised as leaders in their fields and on campus during a Sept. 26 ceremony at the Student Life Center.
